FDA Grants Breakthrough Status to Ifinatamab Deruxtecan for Small Cell Lung Cancer

Daiichi Sankyo and Merck's investigational drug ifinatamab deruxtecan has received FDA Breakthrough Therapy Designation for treating pretreated extensive-stage small cell lung cancer, based on promising clinical trial data, aiming to accelerate its development and approval.